Baatarkhuu Oidov, Gerelchimeg Tsagaantsooj, Munkh-Orshikh Dashchirev, Batsukh Badamnachin, Sarangua Ganbold, Amarsanaa Jazag
Department of Infectious Diseases, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; Mongolian Association for the Study of Liver Diseases, Ulaanbaatar, Mongolia.
Department of Infectious Diseases, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; National Center for Communicable Diseases, Ulaanbaatar, Mongolia.
Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):57-62. doi: 10.5005/jp-journals-10018-1260. Epub 2018 May 1.
Mongolia is located between Russia and China. The total population of Mongolia as of December 2017 is estimated to be 3.2 million people. According to our previous study results, the prevalence of HBV was 11.8%, and anti-HDV was detected in 4.8% among the HBsAg-positive subjects. Interestingly, most HCV infection is caused by genotype 1b. Among all HBV DNA-positive samples, 98.5% were classified into genotype D, and regarding HDV genotypes, all HDV RNA-positive samples, 100%, were classified into genotype I. The second study is the baseline survey of a Nationwide Cancer Cohort Study. Prevalence of HBsAg was 10.6%. Additionally, HCV infection was observed in 9.9%, and 0.8% were coinfected with HBV and HCV among the general population aged from 10 to 64 years. The third study investigated the population-based prevalence of hepatitis B and C virus in apparently healthy population of Ulaanbaatar city, Mongolia. The anti-HCV prevalence was 9.0%. In addition, the prevalence of HBV was 8.0%. The fourth study is on the prevalence of HCV and coinfections among nurses in a tertiary hospital in Mongolia. The prevalence of HCV was 18.9%. Additionally, HBV infection was observed in 23.1%, and 1.2% were coinfected with HCV and HBV. Mongolia has the highest HCC incidence in the world (78.1/100,000, 3.5* higher than China). As a result, the Mongolia government has launched The National Viral Hepatitis Program, which is a comprehensive program that involves all aspects from prevention to care and disease control to meet a reduction goal for morbidity and mortality due to HBV, HCV, and HDV. Consequently, access to antiviral therapies is now improving in Mongolia. Baatarkhuu O, Gerelchimeg T, Munkh-Orshikh D, Batsukh B, Sarangua G, Amarsanaa J. Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. Euroasian J Hepato-Gastroenterol 2018;8(1):57-62.
蒙古国位于俄罗斯和中国之间。截至2017年12月，蒙古国总人口估计为320万。根据我们之前的研究结果，乙肝病毒（HBV）感染率为11.8%，在乙肝表面抗原（HBsAg）阳性受试者中，丁型肝炎病毒抗体（抗-HDV）检测率为4.8%。有趣的是，大多数丙型肝炎病毒（HCV）感染是由1b基因型引起的。在所有乙肝病毒脱氧核糖核酸（HBV DNA）阳性样本中，98.5%被归类为D基因型；关于丁型肝炎病毒（HDV）基因型，所有HDV核糖核酸（HDV RNA）阳性样本（100%）均被归类为I基因型。第二项研究是一项全国癌症队列研究的基线调查。HBsAg感染率为10.6%。此外，在10至64岁的普通人群中，观察到HCV感染率为9.9%，HBV和HCV合并感染率为0.8%。第三项研究调查了蒙古国乌兰巴托市表面健康人群中乙肝和丙肝病毒的人群感染率。抗-HCV感染率为9.0%。此外，HBV感染率为8.0%。第四项研究是关于蒙古国一家三级医院护士中HCV感染率及合并感染情况。HCV感染率为18.9%。此外，观察到HBV感染率为23.1%，HCV和HBV合并感染率为1.2%。蒙古国是世界上肝癌发病率最高的国家（78.1/10万，比中国高3.5倍）。因此，蒙古国政府启动了“国家病毒性肝炎项目”，这是一个全面的项目，涵盖从预防到护理以及疾病控制的各个方面，以实现降低因HBV、HCV和HDV导致的发病率和死亡率的目标。因此，蒙古国目前接受抗病毒治疗的机会正在改善。 巴塔尔胡、格勒尔奇梅格、蒙赫-奥希希格、巴楚克、萨兰瓜、阿玛尔萨纳。蒙古国乙型、丙型、丁型病毒性肝炎及肝细胞癌的流行病学、基因型分布、预后、控制与管理。《欧亚肝脏胃肠病学杂志》2018年；8(1):57 - 62。
